Immunocore Holdings plc (NASDAQ:IMCR) Director Bros. Advisors Lp Baker Buys 807,338 Shares

Immunocore Holdings plc (NASDAQ:IMCR) Director Bros. Advisors Lp Baker acquired 807,338 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the acquisition, the director now directly owns 2,144,060 shares of the company’s stock, valued at $63,721,463.20. The trade was a 60.40 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Immunocore Stock Up 1.2 %

IMCR stock opened at $28.71 on Thursday. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The stock has a market capitalization of $1.44 billion, a P/E ratio of -30.22 and a beta of 0.79. The business has a 50-day moving average of $30.00 and a 200-day moving average of $31.21. Immunocore Holdings plc has a fifty-two week low of $27.19 and a fifty-two week high of $66.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in Immunocore by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 35,492 shares of the company’s stock valued at $1,047,000 after purchasing an additional 420 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Immunocore during the fourth quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. boosted its position in Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock valued at $248,000 after purchasing an additional 960 shares during the last quarter. NEOS Investment Management LLC boosted its position in Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after purchasing an additional 1,102 shares during the last quarter. Finally, Pier Capital LLC boosted its position in Immunocore by 1.4% during the third quarter. Pier Capital LLC now owns 82,480 shares of the company’s stock valued at $2,568,000 after purchasing an additional 1,174 shares during the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IMCR. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a report on Wednesday, March 12th. Needham & Company LLC restated a “buy” rating and issued a $71.00 price target on shares of Immunocore in a report on Wednesday, March 12th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $65.64.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.